Patent Awarded for Low Testosterone Treatment

(Photos8.com)

Repros Therapeutics Inc. in the Woodlands, Texas announced the U.S. Patent and Trademark office has issued a patent for Androxal, the company’s lead treatment for low testosterone in men. This patent claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism, when the sex glands produce little or no hormones.

The company says Androxal is an oral therapy that restores testicular function in men experiencing low testosterone due to secondary hypogonadism. Secondary hypogonadism is commonly related to aging but may result or be a co-morbid state associated with a variety of conditions, including Type II diabetes.

Secondary hypogonadism is not a failure of the testes, but an inability of the pituitary to respond to a low testosterone state by secreting sufficient levels of luteinizing hormone to adequately stimulate the testes. Androxal stimulates the pituitary to secret normal levels of important testicular stimulating pituitary hormones.